allosteric Pol_ DNA polymerase inhibitor
oral activity in BRCA- xenograft (100 mpk QD)
from 165k cmpd biochem. HTS and opt.
Artios Pharma, Cambridge / ICR, London, UK
4. The Artios Pharma selective allosteric Pol_ DNA polymerase inhibitor, ART558, induces synthetic lethality in BRCA-mutant cancer cells and enhances PARP inhibitor activity. Defects in the 53BP1/Shieldin complex (which…